Long-Term Safety and Effectiveness Study of Velsipity 2 mg Tablets in Patients with Moderate to Severe Ulcerative Colitis

What this Trial Is About

This research aims to assess the safety and effectiveness of Velsipity Tablets 2 mg when used long-term, up to 52 weeks, in patients with moderate to severe ulcerative colitis. The study focuses on patients receiving treatment with Velsipity in real-world medical practice. Sponsored by Pfizer, this observational study monitors how the medication performs outside of controlled clinical trials, gathering important safety and symptom remission data. Participants in this study are patients taking Velsipity tablets as prescribed by their doctors. The study observes their treatment over a period of up to one year without assigning any new treatments or placebos. Data collection includes tracking any serious infections, adverse reactions, and symptom improvements during the treatment period. Throughout the study, participants will be monitored for safety outcomes, including the incidence of serious infections and adverse drug reactions, for up to 52 weeks. Researchers will also evaluate the percentage of participants achieving symptomatic remission at 12 weeks and again at 52 weeks. All data will be gathered under actual medical practice conditions, and participants will continue their usual care with their healthcare providers during the study.

An Observational Study to Learn About Velsipity After Long Term Use in Patients With Ulcerative Colitis